Nicotinamide riboside improves muscle mitochondrial biogenesis, satellite cell differentiation, and gut microbiota in a twin study

Lapatto HAK, Kuusela M, Heikkinen A, Muniandy M, van der Kolk BW, Gopalakrishnan S, et al. | Sci Adv | 2023 | Evidence: limited

View on PubMed → | DOI | Publisher

Plain-language summary

Published 2023 in Sci Adv, this work by Lapatto HAK and collaborators tackles a specific question within benefits-focused NMN/NAD+ research.

Key findings reported by the authors

Mechanistic study in Sci Adv (2023) on NAD+/sirtuin/longevity biology
Adds to the foundational literature underlying NMN supplementation rationale
First author: Lapatto HAK

What this means for Malaysian buyers

For readers in Malaysia weighing whether to start or continue NMN supplementation, this paper sits at the limited end of the evidence spectrum. Limited-tier evidence (mouse, in-vitro, or single small pilot) is hypothesis-generating only; do not extrapolate dosing or efficacy claims to humans without supporting replication. Findings here are most directly relevant to benefits decisions, with secondary relevance to science and compare. Our editorial methodology weights human placebo-controlled trials above mouse mechanistic work above review articles.

Where we cite this paper

← Back to research index